Company Encyclopedia
View More
name
Codexi
CDXS.US
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc.
770.89 B
CDXS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking54/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-114.26%E
    • Profit Margin-120.82%E
    • Gross Margin-89.90%E
  • Growth ScoreE
    • Revenue YoY-17.87%E
    • Net Profit YoY-2.99%C
    • Total Assets YoY-16.35%E
    • Net Assets YoY-47.49%E
  • Cash ScoreD
    • Cash Flow Margin-82.77%D
    • OCF YoY-17.87%E
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreD
    • Gearing Ratio68.91%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Owner Opaleye Management Inc Sells 514,341 ($877.8K) Of Codexis Inc [CDXS]

    Opaleye Management Inc Beneficial Owner of Codexis Inc [CDXS] filed a Form 4 on December 1, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/26/25-12/1/25TransactionSaleShares514,341Price$1.71Value$877,826Ending Holdings: 10,134,989 - IndirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    CDXS
    -0.28%
    Reuters·
    US
    CDXS
    -0.28%

    Dir Wolf Sells 8,952 ($14K) Of Codexis Inc [CDXS]

    Wolf Dennis P Director of Codexis Inc [CDXS] filed a Form 4 on November 25, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/21/25TransactionSaleShares8,952Price$1.56Value$13,988Ending Holdings: 138,951 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    CDXS
    -0.28%
    Reuters·
    US
    CDXS
    -0.28%

    Codexis Director Dennis P. Wolf Reports Sale of Common Shares

    Codexis Inc. Director Dennis P. Wolf reported the sale of common shares. The information was published via EDGAR by Codexis Inc. and is available for review. This brief was generated by Public Technologies using AI and is not financial advice.

    Reuters·
    US
    CDXS
    -0.28%
    Reuters·
    US
    CDXS
    -0.28%

    Dir Wolf Files To Sell 8,952 Of Codexis Inc [CDXS]

    Wolf Dennis P, Director of Codexis Inc, filed a Form 144 with the SEC to sell 8,952 shares on November 21, 2025. The sale will be brokered by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted stock within 90 days of filing.

    Reuters·
    US
    CDXS
    -0.28%
    Reuters·
    US
    CDXS
    -0.28%

    Codexis Inc. Files Initial Statement of Beneficial Ownership for CSO Stefan Lutz

    Codexis Inc. has filed an initial statement of beneficial ownership (Form 3) with the U.S. SEC, listing Stefan Lutz, the Chief Scientific Officer, as the beneficial owner. The filing can be accessed via EDGAR. This AI-generated news brief by Public Technologies is for informational purposes only and not financial advice.

    Reuters·
    US
    CDXS
    -0.28%
    Reuters·
    US
    CDXS
    -0.28%
    © 2025 Longbridge｜Disclaimer